480 million company wide NOL, Antigen Assets and B

480 million company wide NOL, Antigen Assets and Buccal delivery assets, plus a long history with regulators and exchanges are highly highly valuable, 2 shelf registrations, dozens and dozens of registrations statements, a proven audited financial compliant legacy - well all that you can’t get anywhere else period, good bad or indifferent as it pertains to people’s past perceptions so be it, however with the non investment community unparalleled, there is no rule book for us however there needs to execution and some semblance of strict adherence to rules.